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Summary

Background An alarming rise in reported Lassa fever cases continues in west Africa. Liberia has the largest reported
per capita incidence of Lassa fever cases in the region, but genomic information on the circulating strains is scarce.
The aim of this study was to substantially increase the available pool of data to help foster the generation of targeted
diagnostics and therapeutics.
Methods Clinical serum samples collected from 17 positive Lassa fever cases originating from Liberia (16 cases) and
Guinea (one case) within the past decade were processed at the Liberian Institute for Biomedical Research using a
targeted-enrichment sequencing approach, producing 17 near-complete genomes. An additional 17 Lassa virus
sequences (two from Guinea, seven from Liberia, four from Nigeria, and four from Sierra Leone) were generated
from viral stocks at the US Centers for Disease Control and Prevention (Atlanta, GA) from samples originating from
the Mano River Union (Guinea, Liberia, and Sierra Leone) region and Nigeria. Sequences were compared with
existing Lassa virus genomes and published Lassa virus assays.
Findings The 23 new Liberian Lassa virus genomes grouped within two clades (IV.A and IV.B) and were genetically
divergent from those circulating elsewhere in west Africa. A time-calibrated phylogeographic analysis incorporating
the new genomes suggests Liberia was the entry point of Lassa virus into the Mano River Union region and estimates
the introduction to have occurred between 300–350 years ago. A high level of diversity exists between the Liberian
Lassa virus genomes. Nucleotide percent difference between Liberian Lassa virus genomes ranged up to 27% in the
L segment and 18% in the S segment. The commonly used Lassa Josiah-MGB assay was up to 25% divergent across
the target sites when aligned to the Liberian Lassa virus genomes.
Interpretation The large amount of novel genomic diversity of Lassa virus observed in the Liberian cases emphasises
the need to match deployed diagnostic capabilities with locally circulating strains and underscores the importance of
evaluating cross-lineage protection in the development of vaccines and therapeutics.
Funding Defense Biological Product Assurance Office of the US Department of Defense and the Armed Forces Health
Surveillance Branch and its Global Emerging Infections Surveillance and Response Section.
Copyright © 2019 Elsevier Ltd. All rights reserved.

U.S. government works are not subject to copyright.

Introduction
Lassa fever is a haemorrhagic disease caused by Lassa
virus, a member of the Mammarenavirus genus in the
family Arenaviridae. Lassa virus was first discovered in
Nigeria in 19691 and later detected in Liberia in 1972.2
Historical evidence and molecular dating indicate that
Lassa virus has circulated in west Africa for hundreds of
years.3 The majority of the confirmed cases are from
the Mano River Union region (Guinea, Liberia, and
Sierra Leone) and Nigeria, but there is evidence of Lassa
virus in Benin, Burkina Faso, Ghana, Côte d’Ivoire, Mali,
and Togo.4
An estimated 300 000 infections of Lassa fever occur
annually, resulting in approximately 5000 deaths.4 For
approximately 80% of these cases, symptoms are mild
and undiagnosed.4 In the other 20% of infections,
common symptoms include back and chest pain, facial
www.thelancet.com/infection Vol 19 December 2019

swelling, haemorrhaging, respiratory distress, and
vomiting.4 The estimated fatality rate for all Lassa fever
infections is 1%, with a 15–20% case fatality rate in
patients who are admitted to hospital.4 Because of the
lack of standardised surveillance programmes, these
numbers are all estimates and may not be an accurate
representation of the true burden of Lassa fever in
west Africa. Standardisation of surveillance has been
complicated by the non-specific symptoms of Lassa fever,
the high level of nucleotide (20–25%) and amino acid
(8–12%) diversity within Lassa virus, and an overall lack
of access to care for a large percentage of the population
in endemic areas, resulting in a majority of clinical cases
going undiagnosed.4–6
To address the lack of effective diagnostics, public
and private groups have started addressing the gaps.
Immunoassays have been developed to detect anti-Lassa
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Research in context
Evidence before this study
Genomic sequencing of epidemics is becoming a powerful tool
to investigate outbreaks, reservoir jumps, and transmission.
Additionally, genomic characterisation enables identification
of possible target erosion in diagnostic assays, informs
countermeasures development including vaccines, and informs
molecular epidemiology tracing of outbreaks. We searched
PubMed without language restrictions in March, 2019, for
articles using the terms “Lassa,” “LASV” or “Lassa virus” with
the terms “genomic epidemiology,” “diagnostic,” “epidemic or
endemic” or “Liberia”. Although numerous previous studies
were discovered, only 59 articles were identified when using
both “Lassa” and “Liberia” terms in the search and most of
these only mentioned Lassa virus in the introduction,
while the main topic of the paper was on another pathogen.
Added value of this study
We obtained 23 near-complete Lassa virus genomes from
Liberia. This represents a ten-fold increase compared with the
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virus IgM, IgG, and Lassa virus antigen, and these
immunoassays have been converted into rapid diagnostic
tests that are pan-Lassa, cheap, and transportable.6,7
However, diagnostic tests labelled "for research use only"
are the only ones that have been made commercially
available to all countries. Typically, immunoassays are
not as sensitive as PCR-based tests, and severe infections
can suppress the production of IgM and IgG and cause
false-negative results.7 A recent study in Sierra Leone did
show greater sensitivity of immunoassays based on Lassa
virus antigen compared with the PCR-based tests that
were being used.8 Molecular diagnostic tests are
considered the most sensitive method, but can produce
false-negative results due to the high degree of genetic
diversity. There are commercially available assays
from three different vendors that have the CE IVD
determination from EU regulators. An appropriate
diagnostic algorithm will require a combination approach
of serological and molecular diagnostics to capture the
wide range of Lassa virus diversity that can be present in
a given country. Reviews of currently available serological
and molecular based diagnostics have been published. 6,7
In 2018, Nigeria had an increase in Lassa fever cases
associated with a case fatality rate of approximately 25%,
causing concern in the global public health community.9,10
Genomic analysis of the circulating strains compared with
historical data indicated that the rise in cases was not
caused by a new circulating variant or sustained human-tohuman transmission, but that it was consistent with
transmission from the rodent reservoir.9,10 During the
same period, Liberia also had a seasonal outbreak of Lassa
fever. Despite the long history of Lassa virus in Liberia,2 a
history of exported cases,11,12 and the high per capita rate of
reported cases (table 1), little is known about the viral

two coding-complete genomes currently found on GenBank.
The new genomes span both temporally (1972–2017)
and spatially (Bong, Nimba, Montserrado, and Lofa counties)
across Liberia. Our data indicate that the Liberian Lassa virus
strains are distinct from those circulating elsewhere and that
improved molecular diagnostics are needed to detect Lassa
fever more effectively in Liberia.
Implications of all the available evidence
The large genomic diversity of Lassa virus emphasises the
need to match deployed diagnostics capabilities with locally
circulating strains and underlines the importance of
evaluating cross-lineage protection in the development
of vaccines and therapeutics. The data also highlight the
need to increase Lassa fever surveillance using appropriate
diagnostics, and to implement strategies that can cope with
high levels of diversity.

genetic diversity circulating in this country. We report
17 Lassa virus genome sequences from clinical cases
(one from Guinea and 16 from Liberia) and 17 from viral
stocks (two from Guinea, seven from Liberia, four from
Nigeria, and four from Sierra Leone). We used these
genomes to infer the evolutionary history of Lassa virus in
Liberia and more broadly in west Africa, and investigated
the appropriateness of current sequence-based diagnostic
tools for detecting Lassa virus lineages from Liberia.

Methods

Sample processing and sequencing
De-identified human serum samples obtained from
patients determined to be positive for Lassa fever by the
Liberian National Reference Laboratory were processed
for sequencing at the Liberian Institute for Biomedical
Research. Accompanying metadata were provided by the
National Public Health Institute of Liberia (ethics
statement is provided in the appendix, p 3). Samples in
Liberia were sequenced on an Illumina MiSeq at the
Liberian Institute for Biomedical Research using an
enrichment-based method as previously described13 with
modifications to enrich Lassa virus. Archival isolates at
the US Center for Disease Control and Prevention (CDC)
Viral Special Pathogens branch in Atlanta, GA, were
sequenced using the TruSeq Stranded mRNA kit on an
Illumina MiniSeq. Additional details on sequencing
methods can be found in the appendix (p 3). The
consensus genome sequences were deposited in
GenBank (appendix p 6).

Phylogenetics and molecular clock analysis
We generated Large (L) and Small (S) segment-level coding
sequence alignments (concatenated open reading frames)
www.thelancet.com/infection Vol 19 December 2019
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2014

2015

2016

2017

2018

Liberia
Reported cases

10

3

96

81

191

Confirmed cases

1

0

14

30

21

0

14·6%

37·0%

11·0%
4·85

Confirmation rate

10·0%

Population size (million)

4·39

4·50

4·61

4·73

Reported per 100 000

0·23

0·07

2·08

1·71

3·94

Confirmed per 100 000

0·02

0·00

0·30

0·63

0·43

Nigeria
Reported cases

929

430

901

1022

3276

Confirmed cases

110

25

101

308

588

Confirmation rate

11·8%

5·8%

11·2%

30·1%

17·9%

176·46

181·18

185·99

190·87

195·88

Reported per 100 000

0·53

0·24

0·48

0·54

1·67

Confirmed per 100 000

0·06

0·01

0·05

0·16

0·30

Population size (million)

2014 and 2015 had known under-reporting in Liberia due to the Ebola virus disease outbreak. Case numbers for Liberia were obtained from the Liberian Ministry of Health
(personal communication) and the Liberia IDSR Epidemiology Bulletin. Case numbers for Nigeria obtained from Nigeria Centre for Disease Control weekly Lassa update
reports. Population data were obtained from Worldometers on Feb 14–19, 2019.

Table 1: Lassa fever cases in Liberia and Nigeria, 2014–18

in Geneious (version 11.1.4; Biomatters, Auckland,
New Zealand) using publicly available sequences covering
at least 80% of the protein-coding portions of either the
L or S genome segment. Maximum-likelihood phylogenies
were generated using RAxML Next Generation with the
GTR+G4 model and 100 bootstrap replicates.14 Root-to-tip
distances using the same dataset were generated with
TempEst (v1.5.1)15 using the best-fitting root option.
Bayesian phylogenies for each of the segment-level
alignments were generated in BEAST (v1.8.4).16 Detailed
methods for the analysis and model comparisons are
provided in the appendix (pp 3–4, p 7).

Lassa virus PCR assay evaluation
Lassa virus specific PCR assays were evaluated using
both in vitro and in silico methods. The in vitro analysis
was done using the two assays deployed in Liberia, the
Nikisins17 and Trombley Josiah-MGB.18 The in silico
analysis was done with the PCR Signature Erosion
Tool (version 1)19 using 16 published Lassa virus assays,
including the Nikisins and Trombley Josiah-MGB.
A final in silico analysis was done by aligning the PCR
primers and probes to all the available Lassa virus
sequences and measuring the number of mismatches
(appendix p 8, pp 12–21, p 24). A more detailed
description of the assay evaluation can be found in the
appendix (p 4).

Role of the funding source
The sponsor of the study had no role in study design,
data collection, data analysis, data interpretation, or
writing of the report. The corresponding author had
full access to all the data in the study and had
final responsibility for the decision to submit for
publication.
www.thelancet.com/infection Vol 19 December 2019

Results

For the Liberia IDSR
Epidemiology Bulletin see
https://nationalphil.org
For more on Worldometers see
http://www.worldometers.info/
world-population

Serum samples positive for Lassa virus were provided by
the National Public Health Institute of Liberia and were
processed and sequenced at the Liberian Institute for
Biomedical Research. We sequenced six samples from
2018 (one was an imported case from Guinea) and
11 archival samples collected between 2011 and 2017
(table 2). Most samples originated from known Lassa
fever hotspots in Bong and Nimba counties. Cases from
Montserrado county probably represent imported cases
from endemic counties—for instance, the patient of
sample LIB-LF17-001 was a resident of Ganta in Nimba
county who became febrile in Montserrado. Codingcomplete genomes were obtained for 12 samples; the
remaining five had gaps in coverage in the L protein
(appendix p 6). We generated 17 coding-complete
sequences from viral stocks of historical reference
samples (two from Guinea, seven from Liberia, four
from Nigeria, and four from Sierra Leone), from the
Centers for Disease Control Viral Special Pathogens
Branch (CDC-VSPB) as well. Of the seven samples
originating from Liberia, three were imported into
the USA with clear epidemiological links to Liberia.11,12
Pairwise comparisons of the new coding-complete
Liberian genomes showed nucleotide diversity that
ranged up to 27% in the L segment and 18% in the
S segment.
Segment-level phylogenetic analysis, including publicly
available Lassa virus genomes, indicated that all of our
Liberian genomes belong to lineage IV (figure 1).20,21
The only exception was the L segment from isolate
807978-P28, which falls outside of the diversity previously
characterised for lineage IV (appendix p 22). The Liberian
Lassa virus genomes are split between two major
clades within lineage IV (labelled IV.A and IV.B in the
1373
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LIB-LF11-003

Country

County or prefecture

District of residence Health-care facility

Specimen type

Collection date

Liberia

Bong

Suakoko

Serum

Feb 20, 2011

Phebe Hospital

LIB-LF11-011

Liberia

Bong

Jorkoqulleh

Phebe Hospital

Serum

April 14, 2011

LIB-LF13-006

Liberia

Nimba

Seclepea Mah

Seclepea Health Center

Serum

April 29, 2013

LIB-LF13-007

Liberia

Nimba

Seclepea Mah

Seclepea Health Center

Serum

April 29, 2013

LIB-LF16-004

Liberia

Bong

Jorkoqulleh

Phebe Hospital

Serum

Feb 26, 2016

LIB-LF16-016

Liberia

Nimba

Garr Bain

Ganta United Methodist Hospital

Serum

April 13, 2016

LIB-LF17-001

Liberia

Montserrado*

Ganta

Ganta United Methodist Hospital

Serum

Jan 9, 2017

LIB-LF17-007

Liberia

Nimba

Seclepea Mah

Ganta United Methodist Hospital

Serum

Jan 9, 2017

LIB-LF17-013

Liberia

Bong

Jorkoqulleh

Phebe Hospital

Serum

Feb 13, 2017

LIB-LF17-019

Liberia

Bong

Jorkoqulleh

Phebe Hospital

Serum

May 4, 2017

LIB-LF17-020

Liberia

Nimba

Seclepea Mah

Phebe Hospital

Serum

May 2, 2017

LIB-LF18-001

Liberia

Bong

NA

NA

Serum

Jan 10, 2018

LIB-LF18-002

Guinea

Yomou

NA

Diécké

Serum

Jan 10, 2018

LIB-LF18-037

Liberia

Nimba

NA

NA

Serum

Feb 13, 2018

LIB-LF18-040

Liberia

Montserrado

NA

NA

Serum

March 2, 2018

LIB-LF18-041

Liberia

Montserrado

NA

NA

Serum

March 3, 2018

LIB-LF18-042

Liberia

Nimba

NA

NA

Serum

March 1, 2018

Samples were provided by the National Public Health Institute of Liberia and were processed and sequenced at the Liberian Institute for Biomedical Research. Country,
county, and prefecture indicate where the patient first presented with symptoms and district of residence indicates where the patient lives. NA=not available.
*Patient was in Montserrado county when becoming febrile but suspected to have become infected in Nimba county.

Table 2: Clinical serum samples positive for Lassa virus collected from Liberia and Guinea

L and S genome segment trees of figures 1 and 2). The
genome segments from the 2018 imported case from
Guinea grouped into clade IV.A which, until now, only
contained partial S genome segments of Liberian origin
(appendix p 23). Clade IV.B had been observed in Guinea,
Liberia, and Sierra Leone and contains the two previously
available coding-complete genomes from Liberia. We
estimated that these two clades diverged approximately
300–350 years ago (L: median 1669, 95% highest posterior
density [HPD] interval 1616–1717]; S: median 1720,
95% HPD interval 1674–1758) by fitting a molecular
clock to the data. Notably, the Liberian isolate
807978-P28 appears to be a reassortant, with an S segment
from clade IV.A and an L segment that does not fall
within lineage IV or V but belongs to a previously
unobserved phylogenetic lineage (appendix pp 22–23).
A more detailed analysis below the lineage level is
provided in the appendix (pp 4–5).
Our molecular clock analysis of lineages IV and V
estimated substitution rates (L: 8·4 × 10–⁴ substitutions
per site per year, 95% HPD interval 7·6 × 10–⁴ to 9·2 × 10–⁴;
S: 8·2 × 10–⁴, 95% HPD interval 7·2 × 10–⁴ to 9·1 × 10–⁴) that
are consistent with previous studies3,21 that included all
five Lassa virus lineages. Our estimates for the time of
most recent common ancestors (tMRCA) for the large
clade from Sierra Leone in lineage IV and lineage V
(figure 2A and 2B) are in line with previous estimates of
about 150 years ago.3,21 However, new genomes from
Liberia and Guinea have pushed back estimates for the
introduction of Lassa virus into the Mano River Union
from about 220 to 300–350 years ago (figure 2A and 2B).3
Both S-based and L-based segment estimates were highly
1374

consistent. Our analysis indicated that with the current
data, Liberia was most likely the entry point for Lassa
virus to the Mano River Union (posterior probability
≥94%), and that the virus was later introduced, at least
four times, into Guinea (0–40, 40–60, 50–130, and
90–280 years ago) and at least once into Sierra Leone
(about 150 years ago; figure 2A and 2B). Root-to-tip
distances were also generated using the identical dataset
and a positive correlation between sampling date and
root-to-tip distance is observed, indicative of molecular
clock signal in the data (figure 2C and 2D).
Liberia was identified as the most likely location for the
MRCA of lineages IV and V, although the low posterior
support indicates ambiguity in this assignment with the
current dataset. Although the S and L segment trees were
highly consistent, they differed substantially in their
tMRCA estimates for the ancestor of lineages IV and V.
This is likely due to the L segment of isolate 807978-P28,
which, as mentioned previously, is consistent with a
reassortment event and does not belong to either lineage
IV or V. Evidence for an additional sequence outside of
lineage IV and V is present in the S genome segment
phylogeny after inclusion of the partial genomes
(appendix p 23). These results suggest that the genetic
diversity of Lassa virus remains undersampled. Thus,
these tMRCAs will likely need further revision with the
addition of more sequence data.
The Liberian National Reference Laboratory in Charles-
ville uses two quantitative real-time PCRs (rtPCRs) assays
to detect Lassa virus: the Lassa Josiah-MGB assay (which
was designed to detect the lineage IV and targets the
glycoprotein precursor [GPC] gene on the S genome
www.thelancet.com/infection Vol 19 December 2019
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A

1

I

2

B

1

I

101

II

2

3

4

5

6

112

II

III
III
V
V
0·5

0·5
A
Match (%)
96·4–100·0
92·7–96·4
89·1–92·7
85·5–89·1
81·8–85·5
Togo
Nigeria
Ghana
Mali
Guinea
Sierra Leone
CÔte d’Ivoirw
Liberia

Match (%)
95·4–100·0
90·7–95·4
86·1–90·7
81·4–86·1
76·8–81·4
72·1–76·8
67·5–72·1

IV

A

IV

83
104

B
B

Figure 1: Maximum-likelihood trees for Lassa virus L and S genome segments sequenced from human infections and reservoir hosts in west Africa
(A) Maximum-likelihood tree for L genome segment. (B) Maximum-likelihood tree for S genome segment. Nodes are coloured based on the country of origin.
Sequences generated from the 2018 cases are outlined in red (see table 2 and appendix p 6 for sample metadata and sequence completeness), other sequences from
this study are outlined in black. For the collapsed clades, the number of contained sequences is specified. Scale bars indicate number of nucleotide substitutions per site.
Roman numerals are used to label previously defined Lassa virus lineages20,21 (see appendix pp 22–23 for subtrees of lineage IV and V which include partial sequences).
The heatmaps to the right of the phylogenetic trees in panels A and B represent the percent identity of the assay target site as presented in the appendix (pp 12–21).
The numbers above the heatmap in panel A represent the following assays: 1 Nikisins22 and 2 Vieth.17 The numbers above the heatmap in panel B represent the
following assays: 1 Bowen,20 2 Coulibaly,23 3 Demby,24 4 Leski,25 5 Olschläger,26 and 6 Safronetz27 (see appendix p 8 for assay sequences and the gene targets).

segment)18 and the La-V assay (designated Nikisins, which
was designed to be a pan-Lassa assay and targets the RNAdependent RNA polymerase [L] gene on the L genome
segment).17 Samples analysed at the Liberian National
Reference Laboratory revealed a large number of
discrepancies between the results of the two assays; the
Nikisins assay often produced positive results for samples
for which the Lassa Josiah-MGB was negative. We aligned
the primers and probes from the two assays to the newly
sequenced Lassa virus genomes and observed a large
www.thelancet.com/infection Vol 19 December 2019

number of mismatches in the target sites of the Lassa
Josiah-MGB assay (75·0–98·4% identity across target sites,
as seen in appendix p 24). Fewer mismatches were present
in the targeted regions of the Nikisins assay (94·6–100%
identity across target sites), mainly due to well-placed
ambiguous bases to account for Lassa virus diversity.
To determine how these mismatches would affect the
ability to detect Lassa virus using the Nikisins or Lassa
Josiah-MGB assays, we did in vitro tests using 16 viral
stocks that originated from west Africa (appendix p 9).
1375
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Four ten-fold dilutions of each viral stock were tested to
see if either assay could detect all the dilutions. The
Nikisins assay was able to detect all the Liberian isolates

at every dilution; however, the Josiah-MGB assay was
only able to detect two of the seven Liberian isolates at all
four dilutions. A correlation was observed between the
B

A

86

83
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IV

IV

B

B

63

72

64

80
65

Sierra Leone
Mali
Côte d’Ivoire
Liberia
Guinea

1450

1500

1550

Montserrado
Nimba
Bong
Lofa

1600

1650

1700

1750

1800

1850

1900

1950

2000

1600 1650

Time (years)

1700

1750

1800 1850 1900 1950 2000

Time (years)

C
2·1

D
R2=0·07

R2=0·24
2·0

2·0
Divergence from root

Figure 2: Temporal maximum
clade credibility trees for
Lassa virus L and S genome
segments sequenced from
human infections and
reservoir hosts in west Africa
(A) Temporal maximum clade
credibility tree for L genome
segment. (B) Temporal
maximum clade credibility tree
for S genome segment.
Only lineages IV and V were
included in this analysis.
Small black circles indicate
clades with posterior
probabilities of at least 90%.
Branches are coloured
according to the inferred
ancestral location of each
lineage. Coloured rings
indicate nodes with ancestral
state posterior probabilities of
at least 90%; nodes below this
threshold are labelled with
their respective probabilities.
The grey violin plots represent
the 95% highest posterior
density intervals for the time
of most recent common
ancestor (tMRCA) for clades
IV.A, IV.B, lineage IV, and
lineages IV and V together
(tree root). Liberian samples
with known county of origin
are indicated with filled circles
and coloured according to
county of origin. Since the
L genome segment of sample
807978-P28 fell outside of the
diversity previous described
for lineages IV it was not used
in the tMRCA analysis for this
lineage. (C) Root-to-tip
distances for the L genome
segment. (D) Root-to-tip
distances for the S genome
segment. Colours indicate
country of origin and the line
represents a simple linear
regression (see appendix p 7
for the BEAST model
comparison for the
L and S genome segments).

A

74

A

1·9
1·9
1·8
1·8

1·7

1·6

1·7

1980

1990
2000
Time (years)

2010

2020

1980

1990
2000
Time (years)

2010

2020
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The Liberian genomes from clade IV.A originate from
Bong, Montserrado, and Nimba counties, and could not be
resolved further than county-level based on the available
metadata. Clade IV.A could be split further into three well
supported subclades that include a grouping of all three
counties, a group of Bong and Montserrado counties, and
a group of just Nimba county. The imported 2018 case
from Guinea also grouped in clade IV.A, specifically in the
subclade that included representatives from Bong,
Montserrado, and Nimba. More details on the movement
of Lassa fever between Liberia and Guinea can be found in
the appendix (p 5).
Clade IV.B has been previously observed in Guinea,
Liberia, and Sierra Leone, and both of the previously
available coding-complete genomes from Liberia belong to
this clade. The majority of Liberian genomes that belong to
this clade are older (originating from 1972–81) and were
isolated from patients diagnosed at Curran Lutheran
Hospital in Zorzor, Liberia, in Lofa County.29,30 One of the
2018 samples, LF18040, falls within a well-supported
subclade of IV.B, which had not been detected for the past
37 years (appendix pp 22–23), showing that this clade
continues to circulate.
Even with additional sequencing data, it appears further
sampling is still needed to capture all the Lassa virus
diversity circulating in Liberia. Multiple indicators of this
include the L and S genome segments of the previously
reported G1200 strain (KM821797 and KM821798), which
group only with sequences from Guinea and Sierra Leone,
Discussion
Liberian Lassa virus genomes are substantially under- and the L segment of strain 807978-P28 and the partial
represented in genomic databases by comparison with S segment from the previously reported Lib05-4094 strain
other Mano River Union countries and Nigeria. As of (GU830819), which both fall outside of lineage IV and V
January, 2019, only two coding-complete Lassa virus (appendix pp 22–23). The available metadata indicate that
genomes, 36 partial S genome segments (27 GPC 807978-P28 is from Bong country, but for G1200 and
at 60–80% coverage and nine nucleoprotein at Lib05-4094 only the country of origin is provided, making
40% coverage), and six partial L genome segments (6–12% it difficult to determine the region of the country in which
coverage of L gene) of Liberian origin were available on this diversity is present. Additional Lassa virus surveillance
GenBank. The short sequence length limits the type of and sequencing of confirmed cases is required to ensure
downstream analyses that can be done compared with that the complete viral diversity in Liberia has been
coding-complete genomes. To address the scarcity of covered.
To expand successful surveillance activities of Lassa fever
genetic information, we obtained coding-complete viral
genomes from confirmed cases during the 2018 Lassa in Liberia, deployed diagnostics need to detect all of the
fever season and from a collection of archival samples. In known genomic diversity. Reliance solely on sequencetotal, we were able to generate 34 near-complete genomes based assays can cause limitations as shown in a
for the L and S segments, 23 of these coming from samples 2015 international quality assessment study.17 In this study,
of Liberian origin (figure 1; table 2; appendix p 6).
Nikisins and colleagues17 observed 11 out of 24 international
These newly sequenced genomes show a large amount reference laboratories had at least one false-negative result
of diversity is present among circulating strains in Liberia. and four of these laboratories did not identify any of the
The genomes were grouped into two distinct and well- samples originating from Liberia.17 One solution would be
supported clades, which we designated IV.A and IV.B. to switch to multiple pan-Lassa assays that target the
When geographical information was available, we found L and S segment (eg, Altona RealStar Nikisins assays), as
that the Liberian genomes grouped according to location done during the 2018 Lassa fever outbreak in Nigeria to
rather than collection dates, which is consistent with help eliminate false-negative results due to potential target
previous observations in Guinea, Nigeria, and Sierra erosion.10 Another solution would be to incorporate
Leone.3,9,10,20,25,28 Most newly sequenced samples grouped in immunoassays into the testing algorithms as has been
clade IV.A, which until now had only been represented in shown in field testing in Sierra Leone.8 The rapid diagnostic
GenBank by partial genomes (figure 1; appendix pp 22–23). antigen test was able to detect samples missed by the

number of mismatches in the target region and ability to
detect all dilutions.
Because of the discrepancies observed between the Lassa
Josiah-MGB assay and the Nikisins assay, we expanded our
evaluation to other published Lassa virus rtPCR assays
using in silico methods. The goal was to quickly evaluate
alternatives for detection of Lassa virus in Liberia and
other endemic regions in Africa. We evaluated 16 published
assays with the PCR Signature Erosion Tool (appendix p 10)
by calculating the percent identity across the target regions
and inferring the minimal number of assays needed to
cover all the diversity in the L and S segment (appendix p 11).
We listed the percent identities of the two L segment assays
and the top six S segment assays along with accession
numbers (appendix pp 12–22) and presented the data as a
heatmap in figure 1 to coordinate with the tips of the
phylogenetic tree. Among the two published L segment
assays tested, the Nikisins assay showed the highest
percent identity across the target site of the analysed Lassa
virus genomes, with a range of 94·6–100% and an average
of 98·6% (figure 1; appendix pp 12–22). Between the six
S segment assays tested, the Bowen20 and Coulibaly23
assays had the highest average identity at 95·2% for Bowen
and 96·1% for Coulibaly (appendix pp 12–22). When
focusing on just genomes of Liberian origin, the Ölschläger
assay26 had the highest average identity for an S segment
assay at 94·2%.
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For more on the Altona kits see
https://www.altona-diagnostics.
com/en/products/reagents-140/
reagents/realstar-real-time-pcrreagents/realstar-lassavirus-rtpcr-kit-ruo.html
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rtPCR assay and new pan-Lassa rapid diagnostic tests
could provide an even broader detection capacity.
The dramatic increase of Lassa fever cases in west Africa,
including Liberia and Nigeria, highlights the growing risk
Lassa virus poses to regional and global health security.
The overwhelming amount of observed Lassa virus
diversity underscores the requirement that medical
countermeasures and diagnostic assays developed against
commonly used Lassa virus laboratory strains are reevaluated locally to ensure effectiveness at preventing,
detecting, and treating all the circulating strains. Our data
identify concerns in the current molecular diagnostic
assays being used in Liberia and highlight the need to
evaluate more recently developed pan-Lassa rtPCR assays
and rapid diagnostic tests in Liberia, to develop a more
comprehensive testing algorithm. Our results are probably
not unique to Liberia and emphasise that these problems
might not be completely resolved if we focus too much on
any given country or region.
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